Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DAS181 for Severe COVID-19: Compassionate Use

Next Previous
Trial Profile

DAS181 for Severe COVID-19: Compassionate Use

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 06 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oplunofusp (Primary)
  • Indications COVID 2019 infections
  • Focus Expanded access; Therapeutic Use

Most Recent Events

  • 01 May 2020 Status changed from recruiting to completed.
  • 02 Apr 2020 According to an Ansun Biopharma Media Release, in the first 14 days, the first two patients no longer required supplemental oxygen, and showed stabilized vital signs, increased oxygen saturation, and resolution of infiltrates on chest CT scans. The third patient, who had been a persistent SARS-CoV-2 carrier for more than 33 days, was completely virus-free before the end of the 10-day DAS181 regimen and met all discharge criteria, and the fourth is currently undergoing treatment.
  • 02 Apr 2020 According to an Ansun Biopharma Media Release, Dr. Ke Hu is the principal investigator.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top